

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number  
**WO 2004/062675 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/706**,  
31/7048, 31/58, A61P 35/00, 25/00, 17/12, 17/02, 17/00,  
15/00, 15/16, 15/08

(74) Agent: WRAY & ASSOCIATES; The Quadrant, Level 4,  
1 William Street, 6000 Perth, Western Australia (AU).

(21) International Application Number:  
PCT/AU2004/000049

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2003900194 15 January 2003 (15.01.2003) AU

(71) Applicant (*for all designated States except US*): SOLBEC  
PHARMACEUTICALS LIMITED [AU/AU]; Level 1,  
10 Stirling Highway, 6009 Nedlands, Australia (AU).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CARTER, Stephen  
John [AU/AU]; 8 Baybury Rise, 6026 Woodvale, Western  
Australia, AU (AU). LAKE, Richard [AU/AU]; 7 Barns-  
ley Road, 6010 Mount Claremont, Western Australia, AU  
(AU).






(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: METHOD OF MODULATING IL-6



(57) Abstract: Use of a glycoalkaloid composition containing at least one Z Glycoalkaloid of formula I, wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the radicals of general formulae (II) to (V); each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>; each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>; each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate; "X" is a radical selected from the group comprising -CH<sub>2</sub>-, -O- and -NH<sub>2</sub>-; and wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative such as one selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxy-sugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; as an IL-6 antagonist.

## "Methods of Modulating IL-6"

### **Field of the Invention**

The present invention relates to methods of modulating IL-6 levels through the use of agents that have been found to have an affect on IL-6 production. The present invention also relates to the use of these agents to treat IL-6 related diseases and disorders, to modulate bone metabolism, to manipulate the immune system and in other applications for which their IL-6 modulating activity renders them useful such as screening methods. More particularly, the present invention relates to a method of killing cells, such as IL-6 producing cells, without causing an increase in IL-6 levels.

### **Background**

IL-6 is a multifunctional cytokine produced by a number of different cell types. It achieves its effects through binding the ligand specific IL-6 receptor and, unlike most other cytokine receptors, the IL-6 receptor is active in both membrane bound and soluble forms.

IL-6 has various physiological effects and a role in many diseases including cancer, autoimmune and inflammatory diseases and infectious diseases such as viral and bacterial infections. The broad range of effects and numerous disease roles of IL-6 make IL-6 inhibitors good therapeutic candidates and the development of such inhibitors continues to be a popular area of research.

With particular regard to cancer, increased IL-6 secretion is an undesirable by-product of many chemotherapy based cancer treatments. The increased IL-6 levels can cause undesirable side effects and may promote the growth and proliferation of cancer cells that survive the chemotherapy that has obvious negative implications.

BEC is a therapeutic agent with anti-cancer activity comprising a mixture of the triglycosides: solasonine and solamargine, their corresponding mono and diglycosides, solasodine (an aglycone) and free sugars. The applicant has now

discovered properties of the glycosides in BEC that render them useful for modulating IL-6 secretion and identify them as candidates for treating IL-6 mediated diseases. Thus, the present invention seeks to provide improved methods for modulating IL-6 production and methods for treating IL-6 mediated diseases based on these newly recognised properties of the glycosides in BEC.

### **Summary of the Invention**

The present invention provides a method of reducing IL-6 production comprising contacting an IL-6 producing cell with an effective amount of a glycoalkaloid composition.

- 10 The present invention also provides a method of disrupting the binding of IL-6 to its receptor comprising contacting the receptor or IL-6 with an effective amount of a glycoalkaloid composition. In a related aspect, the present invention provides a method of reducing the proliferation of IL-6 producing cells comprising contacting said cells with an effective amount of a glycoalkaloid composition.
- 15 The IL-6 modulating activity of the compositions herein render them useful in various applications. Thus, the present invention also provides methods for treating IL-6 related diseases and disorders. They can be used as primary therapy or as part of a combination or adjunct therapy.

- The present invention also provides methods of modulating bone metabolism and treating diseases or disorders associated with bone metabolism as well as the use of the glycoalkaloid compositions herein for modulating or otherwise affecting B cell differentiation, proliferation of thymic and peripheral T cells, induction of T cell differentiation to cytolytic T cells, natural killer cell activation.

- The glycoalkaloid compositions may also be used to reduce tumour cell aggressiveness, metastasis, invasiveness, tumour angiogenesis via a method comprising contacting the cancer with an effective amount of a glycoalkaloid composition.

The present invention also provides a method for modulating or otherwise affecting skin proliferation, megakaryocytopoiesis, macrophage differentiation, neural cell differentiation and proliferation, cachexia, endometriosis, menses or spermatogenesis.

- 5 Finally, the invention provides for the use of the glycoalkaloid compositions herein as IL-6 antagonists and agonists and methods of screening for the same.

### **Brief Description of the Drawings**

Figure 1 is a series of bar charts depicting the IC<sub>50</sub> values (average of three separate experiments) for (A) a glycoalkaloid composition, (B) gemcitabine and  
10 (C) docetaxol in mesothelioma and control cell lines;

Figure 2 is a line graph illustrating the toxicity of a glycoalkaloid composition on two control cell lines measured using the MTT assay;

Figure 3 is a series of line graphs comparing the toxicity of (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol to five mesothelioma cell lines  
15 and two control cell lines [Legend: square = A549; diamond = JU77; circle = LO68; triangle = NO36; crossed square = ONE58; crossed diamond = STY51; and crossed circle = HT29]

Figure 4 is a bar chart illustrating IL-6 production in a range of mesothelioma and control cell lines;

20 Figure 5 is series of line graphs comparing IL-6 concentration and cell viability in the mesothelioma cell line JU77 treated with (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol [Legend: square = pg/mL IL-6; circle = % viable cells; and arrow = IL-6 concentration in the absence of test drug];

Figure 6 is series of line graphs comparing IL-6 concentration and cell viability in  
25 the mesothelioma cell line ONE58 treated with (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol [Legend: square = pg/mL IL-6; circle = %

viable cells; and arrow = IL-6 concentration in the absence of test drug];

Figure 7 is series of line graphs comparing IL-6 concentration and cell viability in the mesothelioma cell line LO68 treated with (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol [Legend: square = pg/mL IL-6; circle = % viable  
5 cells; and arrow = IL-6 concentration in the absence of test drug];

Figure 8 is series of line graphs comparing IL-6 concentration and cell viability in the mesothelioma cell line NO36 treated with (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol [Legend: square = pg/mL IL-6; circle = % viable  
cells; and arrow = IL-6 concentration in the absence of test drug];

10 Figure 9 is series of line graphs comparing IL-6 concentration and cell viability in the mesothelioma cell line STY51 treated with (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol [Legend: square = pg/mL IL-6; circle = % viable  
cells; and arrow = IL-6 concentration in the absence of test drug]; and

Figure 10 is series of line graphs comparing IL-6 concentration and cell viability in  
15 the control cell line A549 treated with (A) a glycoalkaloid composition, (B) gemcitabine and (C) docetaxol [Legend: square = pg/mL IL-6; circle = % viable  
cells; and arrow = IL-6 concentration in the absence of test drug].

## Disclosure of the Invention

### Methods of Modulating IL-6 production

20 The present invention provides a method of reducing IL-6 production comprising contacting an IL-6 producing cell with an effective amount of a glycoalkaloid composition.

The present invention is based on the surprising discovery that the glycoalkaloid compositions described herein have the ability to modulate IL-6 production in a  
25 range of cancer cell lines. In particular, the glycoalkaloid compositions were able to be used to kill cancer cells without causing a concomitant increase in IL-6


levels. Whilst the glycoalkaloids compositions specific mode of action is unknown, the glycoalkaloids may bind to or in some other way affect IL-6 or its receptor such that the ability of IL-6 to bind its receptor is reduced. Alternatively or in addition, the rapid necrotic action of the glycoalkaloids on the cells may  
5 cause the death of the cells without inducing the same signalling pathways associated with apoptotic cell death and thus does not activate the IL-6 pathway. In this regard, it has been observed that at sub-lethal doses the glycoalkaloids cause decreased IL-6 production in IL-6 producing cells.

The present invention also provides a method of disrupting the binding of IL-6 to  
10 its receptor comprising contacting the receptor or IL-6 with an effective amount of a glycoalkaloid composition.

The binding of IL-6 to its receptor causes cell proliferation. Thus, the present invention also provides a method of reducing the proliferation of IL-6 producing cells comprising contacting said cells with an effective amount of a glycoalkaloid  
15 composition.





For the purposes of the present invention the phrase "IL-6 producing cell" includes all cells that are capable of secreting IL-6 such as: stimulated monocytes, fibroblasts, and endothelial cells, macrophages, T-cells and B-lymphocytes, granulocytes, smooth muscle cells, eosinophils, chondrocytes, osteoblasts, mast  
20 cells, glial cells, and keratinocytes, glioblastoma cells and cancer cells including melanoma, squamous cell carcinoma, mesothelioma, basal cell carcinoma, ovarian, hepatic cancer, renal cell carcinoma, gastric cancer, Kaposi's carcinoma, neuroblastoma, prostate carcinoma, non small cell lung cancer, lymphoma, testicular cancer, leukemia, cervical cancer, multiple myeloma, osteo carcinoma,  
25 glioblastoma and colorectal cancer.

The glycoalkaloid composition used in the methods of the present invention may be BEC or other compositions that have at least one glycoalkaloid of formula I:



wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>;

each of  $R^2$  is a radical separately selected from the group consisting of hydrogen,  
10 amino and  $OR^4$ ;

each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

"X" is a radical selected from the group comprising  $-\text{CH}_2-$ ,  $-\text{O}-$  and  $-\text{NH}_2-$ ; and

wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative such as one selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoase), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates. Glycoalkaloid compounds of this general formula are hereinafter referred to as "Z Glycoalkaloids".

Preferably, the glycoalkaloid composition comprises at least two glycoalkaloids. Even more preferably, the composition is essentially without free sugars of the type that inhibit the IL-6 related activity of the glycoalkaloids therein.

When there are two glycoalkaloids in the composition, the ratio of the glycoalkaloids may be between about 6:1 and 1:6, about 1:4 and 4:1, about 1:3 and 3:1 or about 1:2 to 2:1. Alternatively, they may be present in a ratio selected from the group of ratios consisting of approximately: 1:6 - 1:0.5; 1:5; 1:4; 1:3; 1:2, 1:1.5 and 1:1. In this regard, compositions containing particular ratios of glycoalkaloids may have potentiated activity relative to (i) compositions containing the individual glycoalkaloids and (ii) BEC.

When the glycoalkaloids in the composition are solamargine and solasonine in a 1:1 ratio the solamargine and solasonine may be isolated in that they are essentially free of (i) mono and diglycosides and, preferably, essentially free of (ii) free sugars such as mono, di, tri, oligo or polysaccharides and (iii) aglycone. However, unless steps are taken to stabilise the glycoalkaloids, it will be appreciated that even in an isolated glycoalkaloid composition of the present invention there will be a small amount of free sugars and mono and diglycosides that result from degradation of the glycoalkaloids.



Preferably, the glycoalkaloids in the glycoalkaloid composition used in the method of the present invention are triglycoside glycoalkaloids, solasodine glycosides or are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

- 5 The glycoalkaloids in the glycoalkaloid composition used in the methods of the present invention may be chiral, stereoisomers and mixtures thereof including enantiomers and/or diastereoisomers. Furthermore, the glycoalkaloids in the glycoalkaloid composition used in the methods of the present invention may be isolated from natural sources, synthesized or produced by chemically modifying  
10 other glycoalkaloids.

Preferably, the glycoalkaloids in the glycoalkaloid composition used in the methods of the present invention are triglycoside alkaloids and constitute greater than 70%-90% of the glycosides in the composition, more preferably 91-95% and even more preferably 96-100% of the glycosides in the glycoalkaloid composition.

- 15 The IL-6 modulating activity of the compositions herein render them useful in various applications, a number of which are discussed hereunder.

#### Methods of invoking cell death

- The ability of the compounds of the present invention to kill cells without a concomitant increase in IL-6 levels renders them useful as agents for killing or  
20 otherwise reducing cell viability. Thus, the present invention also provides a method for reducing the cell viability comprising the step of contacting said cell with an effective amount of a glycoalkaloid composition.

The cells may be varied and include IL-6 secreting cells and cells that are activated by IL-6. Preferably, the cells are diseased or otherwise undesirable.

- 25 Preferably, the cell viability is reduced by killing the cell. However, cell viability may be reduced by retarding cell proliferation or otherwise affecting the cell in a manner that does not actually kill the cell.

The cell killing ability of the glycoalkaloids compositions also render them useful for targeted killing of cells. Thus, the present invention also provides a glycoalkaloid composition comprising a cell targeting agent that delivers the glycoalkaloids to a predetermined cell or cell type. A related aspect of the invention is a method of killing a cell in a cell population in a targeted manner comprising contacting said population with a glycoalkaloid composition comprising a cell targeting agent adapted to deliver the glycoalkaloid to the target cell.

#### IL-6 Antagonists and Agonists

The present invention also provides for the use of the glycoalkaloid compositions herein as IL-6 antagonists or agonists and methods of screening compounds to identify agents that enhance or block the binding of IL-6 to its receptor.

For example, IL-6 may be contacted with a labelled glycoalkaloid composition of the present invention in the absence or the presence of a candidate agonist or antagonist. The ability of the candidate molecule to bind IL-6 or the IL-6 receptor is reflected in decreased binding of the labelled glycoalkaloid composition. Molecules that bind gratuitously, i.e., without activating the IL-6 receptor and causing signal transduction are most likely to be good antagonists as these may be used to control IL-6 secretion and thus IL-6 related cell proliferation. Molecules that bind IL-6 well and prevent it from binding the receptor are also likely to be useful for controlling IL-6 secretion.

The effects of potential agonists and antagonists on IL-6 secretion may be measured, for instance, by contacting IL-6 producing cells with IL-6 concurrently or prior to contacting an IL-6 producing cell with the antagonist or agonist, and comparing the effect with that of cells contacted only with the IL-6.

Another example of an assay for antagonists is a competitive assay that combines an IL-6 receptor and a potential antagonist with IL-6 under appropriate conditions for a competitive inhibition assay. The IL-6 receptor can be labelled, such as by radioactivity, such that the binding of the receptor to IL-6 can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to IL-6 or the receptor at the same site as the glycoalkaloid compositions of the present invention and thus prevent the binding of the glycoalkaloid compositions. Potential antagonists also may be small organic  
5 molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds to an alternative site on the IL-6 or receptor and prevents the action of the glycoalkaloid composition by excluding its binding to the IL-6 or its receptor.

#### IL-6 related diseases

The ability of the glycoalkaloid compositions herein to modulate IL-6 production  
10 renders them useful for treating IL-6 related diseases. Thus, the present invention also provides for the use of glycoalkaloid compositions to treat an IL-6 related disease.

The effective doses for the IL-6 related applications are preferably approximately 0.05%-1% glycoalkaloids, 0.05%-0.5% glycoalkaloids or 0.05-0.25%  
15 glycoalkaloids.

The IL-6 related disease may be varied and includes: inflammatory diseases such as rheumatoid arthritis; microbial diseases such as HIV, chronic fatigue syndrome and malaria; heart disease such as cardiac myopathy and cardiac disease progression; and other diseases such as Alzheimer's disease, arteriosclerosis,  
20 thyroiditis, Castleman's disease, paraneoplastic symptoms associated with cardiac myxoma, sepsis, psoriasis, diabetes, amyloidosis, hyperlipidemia, polycythemia vera, thrombocythemia and myocardial infarction.

The glycoalkaloid composition may be administered as the primary treatment agent or alternatively may be administered as an adjunct or as a component of a combination therapy. Thus, the present invention also provides for the use of a glycoalkaloid composition in combination with or as an adjunct to another agent  
5 for treating an IL-6 related disease.

The present invention also provides for the use of at least one Z Glycoalkaloid for preparing a medicament for treating an IL-6 related disease.

### Bone Metabolism

IL-6 is involved in bone metabolism and thus the present invention also provides a  
10 method of modulating bone metabolism comprising contacting an osteoblast with an effective amount of a glycoalkaloid composition. These methods include the use of the glycoalkaloid compositions for induction of osteoclastogenesis and osteoclast activity.

The ability of the glycoalkaloid compositions to modulating bone metabolism  
15 renders them useful for treating diseases or disorders associated with bone metabolism. Thus, the present invention also provides a method of treating a bone related disease or disorder comprising administering an effective amount of a glycoalkaloid composition to a subject in need thereof.

The bone related disease or disorder may be varied and includes osteoporosis  
20 and osteoarthritis.

The present invention also provides for the use of at least one Z Glycoalkaloid for preparing a medicament for treating a bone metabolism related disease.

### IL-6 immunological/inflammatory roles

The IL-6 related activity of the glycoalkaloid compositions herein render the useful  
25 for modulating or otherwise affecting B cell differentiation, proliferation of thymic

and peripheral T cells, induction of T cell differentiation to cytolytic T cells, natural killer cell activation.

The present invention also provides for the use of at least one Z Glycoalkaloid for preparing a medicament for treating a immune system related disease.

## 5 Cancer

IL-6 has a role in many cancers. Thus, the present invention also provides a method of treating cancer comprising administering to a subject an effective amount of a glycoalkaloid composition.

10 The cancers treated according to the present invention may be selected from the group comprising: melanoma, squamous cell carcinoma, mesothelioma, basal cell carcinoma, ovarian, hepatic cancer, renal cell carcinoma, gastric cancer, Kaposi's carcinoma, neuroblastoma, prostate carcinoma, non small cell lung cancer, lymphoma, testicular cancer, leukemia, cervical cancer, multiple myeloma, osteo carcinoma, glioblastoma and colorectal cancer.

15 IL-6 is involved in cancer cell proliferation and thus the present invention also provides a method of reducing the proliferation of cancer cells comprising contacting the cancer cell with an effective amount of a glycoalkaloid composition.

IL-6 also has a role in disease progression including the aggressiveness, invasiveness and metastasis of cancer. Thus, the present invention also provides  
20 a method of reducing tumour cell aggressiveness, metastasis, invasiveness, tumour angiogenesis comprising contacting the cancer with an effective amount of a glycoalkaloid composition.

Similarly, IL-6 promotes tumour angiogenesis. Thus, the present invention also provides a method of reducing tumour growth comprising contacting the tumour  
25 with an effective amount of a glycoalkaloid composition.

The effective amounts referred to herein may be determined by a person skilled in the art and preferably the glycoalkaloid compositions comprise about 0.001% -

5% or 10% glycoalkaloids, more preferably 0.01% - 5% or 10% and even more preferably 0.1%- 5% or 10% glycoalkaloids. Put another way the glycoalkaloid compositions may contains about 1 to about 200mg glycoalkaloid, about 100ug-100mg of glycoalkaloids, about 200ug-50mg of glycoalkaloids or 200ug – 10mg glycoalkaloids.

### Other applications

The glycoalkaloid compositions of the present invention may also be used to modulate or otherwise affect skin proliferation, megakaryocytopoiesis, macrophage differentiation, neural cell differentiation and proliferation, cachexia, endometriosis, menses or spermatogenesis. Thus, the present invention also extends to the use of at least one Z Glycoalkaloid for preparing a medicament for treating any one or more diseases resulting from abnormalities in these physiological activities.

The present invention will now be described with reference to the following Examples. The description of the Examples in no way limits the scope of the preceding description.

### **Examples**

#### **Example 1 - The Effects of glycoalkaloids on cell growth and IL-6 production**

##### **(a) Materials and Methods**

##### **(i) Cell lines**

A panel of five human malignant mesothelioma cell lines, established from the pleural fluid of patients with the disease. These cell lines, designed Ju77, Lo68, No36, One58 and Sty51 have been previously described (1). None of the patients from whom the cell lines were derived had been exposed to chemotherapeutic agents. Two cell lines were purchased from ATCC (Rockville, MD) for use as controls: HT29- a human colon adenocarcinoma (ATCC HTB38) and A549- a

human lung adenocarcinoma (ATCC CCL185). These cell lines are representative of tumours that are generally drug resistant but have shown some responses to newer chemotherapy agents. They have previously been shown to have a similar degree of drug resistance to mesothelioma cell lines *in vitro*.

- 5 Cells were maintained in RPMI-1640 containing 5% fetal calf serum (Life Technologies Inc., Melbourne),  $5 \times 10^{-5}$  M 2-mercaptoethanol, 20mM HEPES buffer, 100 IU benzylpenicillin/ml (CSL, Perth) and 50µg gentamicin/ml (David Bull Laboratories, Melbourne), in water saturated air containing 5% CO<sub>2</sub> at 37°C. This growth medium will henceforth be called RF-5. All cells were checked at 3  
10 monthly intervals for Mycoplasma and remained negative to testing.

(ii) Chemotherapy agents

- Docetaxel (Rhone-Poulenc Rorer, NSW) and gemcitabine (Eli Lilly Australia, NSW), vinorelbine (Pierre Fabre Oncology, Hampshire, England) were purchased. All drugs were stored as advised by the manufacturers, made up as necessary in  
15 recommended solvents as stock solutions and used within the period of stability for each agent as determined by the company. Dilutions of each drug were made fresh on the day of use in RF-5 from these stocks.

- (iii) Glycoalkaloid composition – SBP002 was a sterile aqueous solution containing 50mg of the glycoalkaloids - solamargine and solasonine at a 1:1 ratio  
20 in 1mL of acetic acid (pH3-5).

(iv) MTT assay

- Drug sensitivities for each cell line were determined by use of the MTT (Sigma-Aldrich, NSW) assay modified from the method described by Mossman (2). Cells were seeded in 100 µl of RF-5 at appropriate concentrations to maintain  
25 logarithmic growth for the duration of the assay in 96 well flat bottomed tissue culture plates. The plates were incubated for 24 hours to ensure stable growth and then dilutions of drug were added to each well in triplicates to make a total volume of 200 µl. Control wells were made for each plate with no drug or with no

cells. Plates were then incubated for 72 hours after which 50  $\mu$ l of MTT (2 mg/ml) was added and a further 4 hours incubation carried out. Plates were then centrifuged at 2000rpm for 5 minutes after which all media was carefully aspirated. 100 $\mu$ l of DMSO was added to solubilize the formazon crystals and  
5 each plate placed on a shaker for 30 minutes. Optical densities were determined using a SpectraMax 250 plate reader (Molecular Devices) at 570 nm. Plates were blanked on the cell-free medium containing wells that had been treated otherwise in an identical manner.

All experiments were repeated at least three times. The standard deviation for  
10 triplicate values for each experiment was always less than 10%. The IC<sub>50</sub> for each cell line treated with a particular drug was calculated as being the concentration of drug that resulted in a 50% reduction in the optical density of treated cells compared to untreated cells.

#### (v) IL-6 ELISA

15 The IL-6 assay was performed using a human IL-6 ELISA kit (eBioscience, USA) according to the manufacturers protocol. Briefly ninety six well plates were incubated at room temperature overnight with 100 $\mu$ L per well of monoclonal antihuman IL-6 antibody in coating buffer (0.1M Na<sub>2</sub>CO<sub>3</sub>/NaHCO<sub>3</sub>, pH 9.6). The plate was washed five times with PBS and then 200  $\mu$ L of blocking buffer added to  
20 each well and incubated for one hour at room temperature. The plate was then washed five times in PBS with 0.005% Tween 20 (Sigma-Aldrich, NSW). 100 $\mu$ L of each sample to be assayed was added to each well and also IL-6 standard solutions ranging from 0.6-400 pg/ml were used to generate a standard curve.

After a one hour incubation, the plate was washed as above and 100 $\mu$ L of  
25 biotinylated-IL-6 antibody solution added for a further hour. Following further washes, 100 $\mu$ L of streptavidin-HRP conjugate solution was added for 30 minutes and the plates washed. 100 $\mu$ L of ABTS solution was added and following incubation for 30 minutes at 37°C, the plate was read at 405 nm on a SpectraMax



250 plate reader (Molecular Devices) and the concentration of IL-6 for each sample calculated from the standard curve.

Samples for use in the ELISA were prepared by seeding of cells in 96 well plates with or without chemotherapy as described previously. As in the previous  
5 experiments chemotherapy was added 24 hours after cell seeding. For cell lysis experiments 300  $\mu$ l of distilled water was added to each well and lysis of cells was confirmed by visual inspection. Media from these assays was removed at the appropriate time and stored at  $-20^{\circ}\text{C}$  until the ELISA was performed. The concentration of IL-6 for each cell line represents the mean value generated from  
10 three separate experiments. The results from chemotherapy effects on IL-6 production are representative of two or more experiments.

## (b) Results

### (i) In vitro drug sensitivity in mesothelioma

The concentration of each drug required to reduce cell viability by 50% (IC<sub>50</sub>) was  
15 calculated using the MTT assay. The IC<sub>50</sub> values for SBP 002 were calculated by using one fold increments in concentrations close to the IC<sub>50</sub> value. In the case of gemcitabine and docetaxol two fold increases of drug were used. The five mesothelioma cell lines had IC<sub>50</sub>s for SBP 002 ranging from 2.9  $\mu\text{g/ml}$  to 5.4  $\mu\text{g/ml}$  with LO68 being the most sensitive line and ONE58 the least sensitive line  
20 (Figure 1A). The sensitivity of control cell lines A549 and HT29 to SBP 002 also fell within this range.

IC<sub>50</sub> values of cells treated with gemcitabine ranged from 0.8  $\text{ng/ml}$  to 5  $\text{ng/ml}$ , a greater than five fold difference in sensitivity between the greatest and least sensitive cell (Figure 1B). The IC<sub>50</sub> for the lung cancer cell line, A549, fell within  
25 this range (1.75  $\text{ng/ml}$ ). The colon cancer cell line, HT29, had an IC<sub>50</sub> higher than the other examined cell lines (6.7  $\text{ng/ml}$ ). For docetaxel, HT29 was the most sensitive (2  $\text{ng/ml}$ ) as reported previously and the five mesothelioma cell lines had IC<sub>50</sub>s ranging from 4.7  $\text{ng/ml}$  to 7.6  $\text{ng/ml}$  (Figure 1C). The IC<sub>50</sub> for A549, fell

within this range at 5.4 ng/ml. These results for gemcitabine and docetaxol are all similar to those reported previously (3).

#### (ii) Drug Toxicity

SBP 002 was toxic to both mesothelioma and control cells alike (Figure 2).  
5 Viability remains high until a critical dose at around 5 ug/ml SBP 002 is reached. Thereafter viability falls sharply within a small dose increment. This contrasts gemcitabine and docetaxol where the dose response curve is linear over a much broader range (Figures 3B and 3C). For example, the death of NO36 cells treated with gemcitabine reaches a plateau at a concentration of approximately 3ng/ml  
10 and at 10 ng/ml gemcitabine there is still 50% viability. In the case of docetaxol the plateau effect is clear for all cell lines (Figure 5C). This suggests that SBP 002 is a more potent drug than those previously investigated by our research group (3).

#### (iii) IL6 secretion from mesothelioma cells

15 The five mesothelioma cell lines produced different amounts of IL-6 when grown in culture for 96 hours (Figure 4). The greatest producers of IL-6 were ONE58 and JU77 while NO36 produced the least. The control cell line A549 produced minimal amounts of IL-6. However, no detectable IL-6 was secreted by HT29. The concentration of IL-6 for each cell line was determined from the final  
20 concentration present in the growth media following 96 hours of incubation. It should be noted that all cells were seeded at the same density, but because of variations in proliferation rates between the cell lines, the final cell numbers would have varied following 96 hours of growth. The doubling times for the five mesothelioma cell lines range from 25.3 hours to 33 hours. The cell lines ONE58  
25 and NO36 were two of the slower growing cell lines and the difference in production of IL-6 between these cell lines and the others would have increased if total cell numbers were taken into account.

(iv) IL-6 secretion from mesothelioma cells treated with chemotherapy

- Mesothelioma and control cells treated with low concentrations of SBP 002 produced the same amount of IL-6 as untreated cells (Figures 5-10). IL-6 production remained constant at this level as the concentration of SBP 002 was increased. Thus SBP 002 did not mimic the effect reported for gemcitabine whereby treatment of mesothelioma cells with concentrations of gemcitabine sufficient to produce a 5-30% reduction in relative cell growth, resulted in a decrease in the IL-6 concentration by up to one half of that released by untreated cells (3).
- 10 Treatment of cells with concentrations of docetaxol below its IC50 concentration did not effect IL-6 production compared to untreated cells. However, in the case of both gemcitabine and docetaxol a surge in IL-6 production was measured as the concentration of each drug approached its IC50 value (Figures 5-10). This surge of IL-6 did not occur when cells were treated with SBP 002. Instead, at
- 15 concentrations above the IC 50 for SBP 002, IL-6 production decreased in proportion to the % loss of cell viability (Figures 5-10).

Example 2 – Treatment of Psoriasis

(a) Materials/Methods

- A 0.1% preparation of SBP002 in an aqueous cream base was applied daily to
- 20 lesions on a subject suffering from psoriasis. This level represents a substantially lower dose than that applied to treat cancer.

(b) Results

Within 28 days the treated lesions had healed and been replaced by normal skin.

- It was also noted that when the cream was applied to the calf or elbow lesions
- 25 distal to the application point on the foot and hand also disappeared, evidencing systemic action.


Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

## 5 References

1. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, Robinson BW: Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. *Int.J.Cancer* 47:285-290, 1991
- 10 2. Mossman.T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of Immunology Methods* 65: 55-63
3. McClaren MJ, Robinson BWS, Lake RA (2000) New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. *Cancer*  
15 Chemother Pharmacol 45: 502-508.

# The Claims Defining the Invention are as Follows




1. Use of a glycoalkaloid composition containing at least one containing at least one Z Glycoalkaloid of formula I:




5

wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



or



10

each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ;

each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ;

each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

"X" is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

5 wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative such as one selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose,  
10 ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar alcohols,  
15 sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;

as an IL-6 antagonist.

2. A method for screening for IL-6 agonists or antagonists comprising the steps  
20 of contacting a glycoalkaloid composition containing at least one Z Glycoalkaloid with an IL-6 producing cell in the presence of a candidate agonist or antagonist and assessing IL-6 levels.
3. A method according to claim 2 wherein the Z Glycoalkaloid or the IL-6 receptor is labelled.
- 25 4. A method of reducing IL-6 production comprising contacting an IL-6 producing cell with an effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid.

5. A method of disrupting the binding of IL-6 to its receptor comprising contacting the receptor or IL-6 with an effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid.
6. A method of reducing the proliferation of IL-6 producing cells comprising contacting said cells with an effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid.
7. A method according to any one of claims 4 to 6 wherein the glycoalkaloid composition is essentially without free sugars of the type that inhibit the IL-6 related activity of the glycoalkaloids therein.
8. A method according to any one of claims 4 to 7 wherein the Z Glycoalkaloids triglycoside glycoalkaloids, solasodine glycosides or are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.
9. A method according to any one of claims 4 to 8 wherein the glycoalkaloid composition comprises two Z Glycoalkaloids.
10. A method according to claim 9 wherein the ratio of the Z Glycoalkaloids is between about 6:1 and 1:6.
11. A method according to claim 9 wherein the ratio of the Z Glycoalkaloids is about 1:1.
12. A method according to claim 9 wherein the Z Glycoalkaloids are solamargine and solasonine in a 1:1 ratio and the solamargine and solasonine are essentially free of (i) mono and diglycosides.
13. A method according to claim 12 wherein the solamargine and solasonine are also essentially free of (i) free sugars such as mono, di, tri, oligo or polysaccharides and (ii) aglycone.

14. A method according to any one of claims 4 to 13 wherein the Z Glycoalkaloids are chiral, stereoisomers and mixtures thereof including enantiomers and/or diastereoisomers.
15. A method according to any one of claims 4 to 14 wherein the Z Glycoalkaloids are isolated from natural sources.
16. A method according to any one of claims 4 to 6 wherein the Z Glycoalkaloids are triglycoside alkaloids and constitute greater than 70%-90% of the glycosides in the composition.
17. A method according to any one of claims 4 to 6 wherein the Z Glycoalkaloids are triglycoside alkaloids and constitute 91-95% of the glycosides in the composition.
18. A method according to any one of claims 4 to 6 wherein the Z Glycoalkaloids are triglycoside alkaloids and constitute 96-100% of the glycosides in the composition.
19. A method according to any one of claims 4 to 6 wherein the glycoalkaloid composition is BEC.
20. The use of a glycoalkaloid composition containing at least one Z Glycoalkaloid to treat an IL-6 related disease.
21. The use according to claim 20 wherein the IL-6 related disease is selected from the group comprising: inflammatory diseases such as rheumatoid arthritis; microbial diseases such as HIV, chronic fatigue syndrome and malaria; heart disease such as cardiac myopathy and cardiac disease progression; and other diseases such as Alzheimer's disease, arteriosclerosis, thyroiditis, Castleman's disease, paraneoplastic symptoms associated with cardiac myxoma, sepsis, psoriasis, diabetes, amyloidosis, hyperlipidemia, polycythemia vera, thrombocythemia and myocardial infarction.




22. The use according to claim 20 or 21 wherein the glycoalkaloid composition is administered in combination with or as an adjunct to another agent for treating the IL-6 related disease.
23. A method of modulating bone metabolism comprising contacting an osteoblast  
5 with an effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid
24. A method according to claim 23 wherein the glycoalkaloid composition induces osteoclastogenesis and/or osteoclast activity.
25. A method of treating a bone related disease or disorder comprising  
10 administering an effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid to a subject in need thereof.
26. A method according to claim 25 wherein the bone related disease or disorder is osteoporosis or osteoarthritis.
27. Use of a glycoalkaloid composition containing at least one Z Glycoalkaloid to  
15 modulate or otherwise affect B cell differentiation, proliferation of thymic and peripheral T cells, induction of T cell differentiation to cytolytic T cells, natural killer cell activation.
28. A method of reducing the proliferation of cancer cells comprising contacting the cancer cell with an effective amount of a glycoalkaloid composition  
20 containing at least one Z Glycoalkaloid
29. A method of reducing tumour cell aggressiveness, metastasis, invasiveness, tumour angiogenesis comprising contacting the cancer with an effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid.
30. A method of reducing tumour growth comprising contacting the tumour with an  
25 effective amount of a glycoalkaloid composition containing at least one Z Glycoalkaloid.


31. Use of a glycoalkaloid composition containing at least one Z Glycoalkaloid to modulate or otherwise affect one or more of skin proliferation, megakaryocytopoiesis, macrophage differentiation, neural cell differentiation and proliferation, cachexia, endometriosis, menses or spermatogenesis.
- 5 32. A method for reducing cell viability comprising the step of contacting said cell with an effective amount of a glycoalkaloid composition.
33. A method according to claim 32 wherein the cell is and IL-6 secreting cell or a cell that is activated by IL-6.
- 10 34. A method according to claim 32 or 33 wherein the cell is diseased or otherwise undesirable.
35. A method according to any one of claims 32 to 34 wherein cell viability is reduced by killing the cell.
36. A method according to any one of claims 32 to 34 wherein cell viability is reduced by retarding cell proliferation.
- 15 37. A glycoalkaloid composition comprising at least one Z Glycoalkaloid and a cell targeting agent that delivers the glycoalkaloid to a predetermined cell or cell type.
- 20 38. A method of killing a cell in a cell population in a targeted manner comprising contacting said population with a glycoalkaloid composition comprising at least on Z Glycoalkaloid and a cell targeting agent adapted to deliver the glycoalkaloid to the target cell.

1/10


Figure 1.



A




B



C


2/10

Figure 2




3/10


Figure 3



A



B



C

Figure 4





Figure 5



6/10

Figure 6






Figure 7






Figure 8




9/10

Figure 9



10/10

Figure 10.



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/000049

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. <sup>7</sup>: A61K 31/706, 31/7048, 31/58; A61P 35/00, 25/00, 17/12, 17/02, 17/00, 15/00, 15/16, 15/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DWPI, Medline: solasonine, solamargine, bec, tomatine, solanocapsine, aminofurostane, IL and 6, interleukin and 6

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2004/002497 A (SOLBEC PHARMACEUTICALS LTD.) 8 January 2004 Entire document, especially pages 1-28	1-4, 6-38
X	WO 2003/029269 A (GLYCOMED SCIENCES LTD.) 10 April 2003 pages 1-9	21, 27-32, 34-38
X	WO 2000/061153 A (CURA NOMINEES PTY. LTD.) 19 October 2000 Entire document, especially pages 1-26	1-4, 6-38
X	WO 1991/010743 A (CURA NOMINEES PTY. LTD.) 25 July 1991 Entire document, especially pages 1-22	1-4, 6-38



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
16 March 2004

Date of mailing of the international search report  
30 MAR 2004

Name and mailing address of the ISA/AU  
AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaaustralia.gov.au  
Facsimile No. (02) 6285 3929

Authorized officer  
G.J. McNEICE  
Telephone No : (02) 6283 2055

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2004/000049

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	2004002497						
WO	2003029269						
WO	200061153	AU	35454/00	CA	2369272	EP	1181022
		WO	0061153				
WO	199110743	AT	188036	AU	71594/91	BR	9105952
		CA	2073855	EP	0515386	EP	0515386
		JP	3168542	KR	213805	SG	50585
		US	5958770	WO	9110743		
END OF ANNEX							